RedHill Biopharma Ltd. Stock: price and insider trades · United States
RedHill Biopharma Ltd.: what insiders have been doing
RedHill Biopharma Ltd. is a listed company. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 8 November 2026, brought 3 filings signed by 1 insider.
No insider bought on the market over the period, while 1 insider filed 3 sales totalling €3,860. One trade stands out by size: a sale of €1,364 from Raday Gilead, disclosed on 22 April 2026.
Compared with its exchange (5,808 companies, median 19 filings), a count of 3 filings is below the norm. Looking back to 2026, when coverage begins, insiders filed no purchases and 3 sales.
Typically, a trade is published a median of 5 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 14,310,000 shares0.032% mcap32.7% of flowOrdinary SharesSEC:0001178913-26-004715:0
- 14,130,000 shares0.043% mcap47.5% of flowOrdinary SharesSEC:0001178913-26-003473:0
- 15,740,000 shares52.5% of flowOrdinary SharesSEC:0001178913-26-002183:0
3 of 3 declarations
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd. is a biopharmaceutical company focused on developing treatments for gastrointestinal diseases. It is listed on NASDAQ under the ticker RDHL.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
